Lyka Labs LimitedQ1 FY27 Results & Financial Update
Lyka Labs Limited: Q1 FY27 consolidated results and company financials – revenue ₹42.31 Cr, PAT ₹2.05 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Lyka Labs price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Lyka Labs Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Lyka Labs Limited reported its unaudited consolidated financial results for the first quarter ended June 30, 2026, demonstrating profitable operations during the period under review.
For Q1 FY27, the company recorded consolidated revenue from operations of INR 42.31 crore, accompanied by other income of INR 0.42 crore, bringing total consolidated income to INR 42.73 crore.
Total expenses for the quarter aggregated to INR 40.78 crore, enabling the company to achieve a consolidated profit before tax (PBT) of INR 1.95 crore.
After accounting for tax adjustments, the consolidated profit after tax (PAT) for the quarter stood at INR 2.05 crore, reflecting positive bottom-line performance.
Basic and diluted earnings per share (EPS) for the quarter were recorded at INR 0.57 (not annualized), indicating positive earnings accretion for equity shareholders during the period.
The financial statements reflect the accounting impact of the amalgamation of Lyka Export Limited into Lyka Labs Limited pursuant to the NCLT Ahmedabad Bench order dated March 16, 2026, which required restatement of prior period figures under IND AS 103.
During the quarter, the Board of Directors also approved the complete divestment of the company's equity stake in its subsidiary, Lyka BDR International Limited, aligning with strategic portfolio rationalization efforts.
For the first quarter of fiscal year 2027 ended June 30, 2026, Lyka Labs reported consolidated revenue from operations of INR 42.31 crore.
01 · Business model
What does Lyka Labs do?
Lyka Labs Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of a diverse range of pharmaceutical formulations and medical products.
The company operates out of its registered and manufacturing base in Ankleshwar, Gujarat, and maintains its corporate office in Mumbai, Maharashtra.
Lyka Labs primarily operates within a single business segment classified under Pharmaceuticals, catering to both domestic and international healthcare markets through its extensive product portfolio.
The corporate structure of the company includes subsidiaries and operational linkages designed to streamline its manufacturing footprint and commercial distribution network across various therapeutic categories.
02 · Historical context
What shaped the business before this quarter
Previously, the Ahmedabad Bench of the Hon'ble National Company Law Tribunal sanctioned the Scheme of Amalgamation for the merger of Lyka Export Limited (the transferor company) with Lyka Labs Limited (the transferee company) under Sections 230 to 232 of the Companies Act, 2013, via an order dated March 16, 2026.
03 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹42.31 Cr |
| Total income | ₹42.73 Cr |
| Profit before tax | ₹1.95 Cr |
| Profit after tax | ₹2.05 Cr |
| EPS | ₹0.57 |
04 · Why it moved
Why the quarter looked the way it did
What drove revenue
Revenue from operations for the quarter ended June 30, 2026, reached INR 42.31 crore, supported by pharmaceutical formulation sales across domestic and international channels.
The company generated INR 0.42 crore in other income during Q1 FY27, contributing to a total consolidated income of INR 42.73 crore.
Revenue from operations of INR 42.31 crore was primarily driven by commercial sales of pharmaceutical formulations within the company's single operating segment.
The company recorded INR 0.42 crore in other income during the quarter, contributing to total consolidated income of INR 42.73 crore.
What drove margins
Cost of materials consumed stood at INR 11.20 crore, purchase of stock-in-trade was INR 7.50 crore, and changes in inventories of finished goods, work-in-progress, and stock-in-trade registered a positive adjustment of INR 2.26 crore.
Employee benefits expense for the quarter was INR 1.15 crore, while other expenses aggregated to INR 9.82 crore.
Finance costs for Q1 FY27 were reported at INR 1.01 crore, and depreciation and amortization expenses accounted for INR 2.01 crore.
Cost of materials consumed was INR 11.20 crore, while purchases of stock-in-trade stood at INR 7.50 crore for the quarter.
Changes in inventories of finished goods, work-in-progress, and stock-in-trade provided a positive variance of INR 2.26 crore.
Employee benefits expense was recorded at INR 11.49 crore, and other expenses stood at INR 9.82 crore, reflecting operational overheads.
Depreciation and amortization expenses were INR 2.01 crore, while finance costs amounted to INR 1.01 crore for the quarter.
05 · Segments, products & geography
Which parts of the business are doing the work
Segments and products
The company operates in one primary business segment, namely 'Pharmaceuticals', in accordance with IND AS 108 reporting requirements.
The company operates and reports in one primary business segment, namely 'Pharmaceuticals', in accordance with accounting standards.
06 · Capacity, projects & execution
What is being built, commissioned or delivered
Capacity, production and utilisation
Production activities are anchored by the company's manufacturing plant situated in the GIDC Industrial Estate in Ankleshwar, Gujarat.
07 · Strategy & new businesses
How the company is trying to change its growth mix
The Board of Directors approved the divestment of the 100% equity stake held in subsidiary company Lyka BDR International Limited, which contributed total income of INR 10.55 lakh (representing 8% of consolidated income) and a net worth of negative INR 4.49 lakh in the previous financial year ended March 31, 2026.
The Board of Directors approved the divestment of the company's 100% equity stake in subsidiary Lyka BDR International Limited, authorizing the Audit Committee to finalize transaction details.
08 · Reported developments
What changed operationally
The company returned to profitability with a consolidated profit after tax of INR 2.05 crore and basic EPS of INR 0.57 for Q1 FY27.
Statutory auditors D. Kothary & Co. issued an unqualified review conclusion on both the standalone and consolidated unaudited financial results for the quarter ended June 30, 2026.
The company delivered a positive consolidated net profit after tax of INR 2.05 crore for Q1 FY27, turning around from losses in preceding quarters.
Statutory auditors D. Kothary & Co. expressed an unmodified, unqualified review conclusion on both standalone and consolidated financial statements.
09 · Pressure points & risks
What is not going smoothly
Subsidiary Lyka BDR International Limited reported a net loss after tax of INR 0.05 crore (INR 5.36 lakh) for the quarter ended June 30, 2026, and a negative net worth as of March 31, 2026.
Subsidiary Lyka BDR International Limited reported nil revenues and a net loss after tax of INR 5.36 lakhs for the quarter ended June 30, 2026.
10 · Beyond the numbers
What changed beyond the numbers
Reported update
Audit Committee Delegation for Divestment
The Board of Directors has delegated requisite authority to the Audit Committee to execute and finalize all matters relating to the divestment of Lyka BDR International Limited.
Reported update
Subsidiary Divestment Metrics
Lyka BDR International Limited contributed total income of INR 10.55 lakh (representing 8% of consolidated income) during the previous financial year ended March 31, 2026, and held a negative net worth of INR 449.17 lakh.
11 · Key Q&A
The quarter, answered directly
What does Lyka Labs do?
Lyka Labs Limited is an Indian pharmaceutical company engaged in the manufacturing, marketing, and distribution of a diverse range of pharmaceutical formulations and medical products.
What is the clearest takeaway from Q1 FY27?
Lyka Labs Limited reported its unaudited consolidated financial results for the first quarter ended June 30, 2026, demonstrating profitable operations during the period under review.
What drove revenue or demand?
Revenue from operations for the quarter ended June 30, 2026, reached INR 42.31 crore, supported by pharmaceutical formulation sales across domestic and international channels.
What mattered most for margins or profitability?
Cost of materials consumed stood at INR 11.20 crore, purchase of stock-in-trade was INR 7.50 crore, and changes in inventories of finished goods, work-in-progress, and stock-in-trade registered a positive adjustment of INR 2.26 crore.
What changed operationally beyond the headline numbers?
Production activities are anchored by the company's manufacturing plant situated in the GIDC Industrial Estate in Ankleshwar, Gujarat.
What are the main pressure points disclosed for the quarter?
Subsidiary Lyka BDR International Limited reported a net loss after tax of INR 0.05 crore (INR 5.36 lakh) for the quarter ended June 30, 2026, and a negative net worth as of March 31, 2026.
12 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
13 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Completion of Subsidiary Divestment: Monitor the definitive agreement execution, completion timeline, and consideration terms regarding the divestment of 100% equity in Lyka BDR International Limited.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.